GLP-1 and Intestinal Diseases

被引：37
|
作者：
Hunt, Jenna Elizabeth [1 ]
Holst, Jens Juul [1 ,2 ]
Jeppesen, Palle Bekker [3 ]
Kissow, Hannelouise [1 ,2 ]
机构：
[1] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, DK-2200 Copenhagen, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn, Ctr Basic Metab Res, DK-2200 Copenhagen, Denmark
[3] Rigshosp, Dept Med Gastroenterol & Hepatol, DK-2200 Copenhagen, Denmark
来源：
BIOMEDICINES | 2021年 / 9卷 / 04期
关键词：
GLP-1; intestinal disease; short-bowel syndrome (SBS); mucositis; inflammatory bowel disease (IBD); coeliac disease; GLUCAGON-LIKE PEPTIDE-1; INFLAMMATORY-BOWEL-DISEASE; RECEPTOR AGONISTS; GLYCEMIC CONTROL; KAPPA-B; PLASMA; CELLS; MECHANISMS; SECRETION; EXENATIDE;
D O I：
10.3390/biomedicines9040383
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1 ' s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
引用
收藏
页数：14
相关论文
共 50 条
  • [21] Hypoglycemic effect of intestinal electrical stimulation is medicated via GLP-1
    Ouyang, X.
    Li, S.
    Yin, J.
    Chen, J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 : 35 - 35
  • [22] Gastric and biliopancreatic secretions but not intestinal motility are inhibited by GLP-1 in humans
    Keller, J
    Franke, A
    Goebell, H
    Layer, P
    GASTROENTEROLOGY, 1997, 112 (04) : A1162 - A1162
  • [23] Intestinal mTOR regulates GLP-1 production in mouse L cells
    Geyang Xu
    Ziru Li
    Li Ding
    Hong Tang
    Song Guo
    Hongbin Liang
    Huadong Wang
    Weizhen Zhang
    Diabetologia, 2015, 58 : 1887 - 1897
  • [24] Intestinal mTOR regulates GLP-1 production in mouse L cells
    Xu, Geyang
    Li, Ziru
    Ding, Li
    Tang, Hong
    Guo, Song
    Liang, Hongbin
    Wang, Huadong
    Zhang, Weizhen
    DIABETOLOGIA, 2015, 58 (08) : 1887 - 1897
  • [25] Distinct activation of GLP-1 receptor by exendin-4 and GLP-1
    Montrose-Rafizadeh, C
    Yang, H
    Pritchette, LA
    Eng, J
    DIABETES, 1998, 47 : A192 - A192
  • [26] Clocking Up GLP-1: Considering Intestinal Rhythms in the Incretin Effect
    Reimann, Frank
    Reddy, Akhilesh B.
    DIABETES, 2014, 63 (11) : 3584 - 3586
  • [27] Pulmonary administration of GLP-1 (GLP-1 Technosphere powder) I: Kinetics
    Cassidy, J.
    Baughman, R.
    Costello, D.
    Levy, B.
    van Vliet, A.
    Diaz, M.
    Damico, C.
    Richardson, P.
    DIABETOLOGIA, 2008, 51 : S346 - S346
  • [28] Pulmonary administration of GLP-1 (GLP-1 technosphere powder) II: Dynamics
    Costello, D.
    Baughman, R.
    Levy, B.
    van Vliet, A.
    Price, A.
    Diaz, M.
    Damico, C.
    Richardson, P.
    DIABETOLOGIA, 2008, 51 : S346 - S347
  • [29] Neuroprotective effects of GLP-1 receptor agonists and their potential in retinal diseases
    Mouhammad, Zaynab Ahmad
    von Spreckelsen, Alexander
    Bermudez, Mariana Yolotzin Garcia
    Vohra, Rupali
    Williams, Pete
    Kolko, Miriam
    ACTA OPHTHALMOLOGICA, 2024, 102
  • [30] Novel GLP-1 secretagogues as neuroprotective agents for retinal neurodegenerative diseases
    Powell, Folami Lamoke
    Thomas, Shakera
    Martin, Pamela M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
12345